Fujifilm introduces Synapse Pathology at the United States and Canadian Academy of Pathology Annual Meeting
Press releases may be edited for formatting or style | March 09, 2023
Health IT
*Lujan G, Kellough DA, Frankel WL, Chhibber NN, Parwani AV, Chen W, Li Z, Lombardo A, Walsh J, Lloyd M. Faster Than Glass: A Digital Pathology Workflow Unlocks Major Time-Savings. United States & Canadian Academy of Pathology’s (USCAP) 111th Annual Meeting. Los Angeles, CA. March 19-24, 2022.
About Fujifilm
Reveal 35C: spectral bedside imaging, no extra dose, now available in the EU
KA Imaging’s Reveal 35C detector, currently available as an upgrade solution in the US and selected geographies, can now be sold in the European Union. The detector recently obtained the CE Mark. Contact us at sales@kaimaging.com to book a free demo.
FUJIFILM Healthcare Americas Corporation is a leading innovator in diagnostic and enterprise imaging solutions designed to meet the evolving needs of healthcare across prevention, diagnosis, and treatment. Fujifilm’s medical imaging portfolio includes solutions for digital radiography, mammography, computed tomography, magnetic resonance imaging, ultrasound, endoscopy, and endosurgery. The Synapse® Enterprise Imaging portfolio provides healthcare professionals with the imaging and data access needed to deliver a complete patient record. REiLI®, Fujifilm’s artificial intelligence initiative, combines Fujifilm’s rich image-processing heritage with cutting-edge AI innovations to inspire a new tier of clinical confidence. The In-Vitro Diagnostic portfolio provides the golden standard of molecular based immunoassay technology for liver surveillance, cutting edge clinical diagnostic chemicals for leading laboratories across the country and diagnostic chemicals for OEM white labeling products. The company is headquartered in Lexington, Massachusetts.
FUJIFILM Holdings Corporation, Tokyo, leverages its depth of knowledge and proprietary core technologies to deliver Value from Innovation in our products and services in the business segments of healthcare, materials, business innovation, and imaging. Our relentless pursuit of innovation is focused on providing social value and enhancing the lives of people worldwide. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information about Fujifilm’s Sustainable Value Plan 2030, click here. For the year ended March 31, 2022, the company had global revenues of approximately 2.5 trillion yen (21 billion $USD at an exchange rate of 122 yen/dollar).
Back to HCB News
2(current)
You Must Be Logged In To Post A CommentRegisterRegistration is Free and Easy. Enjoy the benefits of The World's Leading New & Used Medical Equipment Marketplace. Register Now! |
|
